VYNE Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 |
| Cost of revenue | — | — | — | — | $3.3M |
| Selling, general & administrative | — | — | — | $16.4M | $20.3M |
| Research and development | $19.2M | $30.9M | $16.3M | $18.4M | $19.5M |
| Operating income | -$29.7M | -$43.6M | -$29.3M | -$34.3M | -$38.9M |
| Interest expense | — | — | — | $0 | $5.6M |
| Pretax income | -$26.7M | -$39.8M | -$27.9M | -$33.9M | -$44.7M |
| Income tax expense | $4,000 | $4,000 | $0 | $13,000 | -$448,000 |
| Net income | -$26.5M | -$39.8M | -$28.5M | -$23.2M | -$73.3M |
| Balance Sheet | |||||
| Cash and equivalents | $24.0M | $19.9M | $30.6M | $30.9M | $42.2M |
| Current assets | $30.0M | $64.4M | $96.0M | $38.3M | $63.2M |
| Total assets | $30.2M | $66.9M | $97.7M | $40.8M | $67.0M |
| Current liabilities | $2.4M | $14.8M | $7.5M | $9.3M | $18.4M |
| Total liabilities | $2.4M | $14.8M | $8.9M | $9.3M | $18.4M |
| Stockholders' equity | $27.8M | $52.1M | $88.7M | $31.2M | $48.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$33.1M | -$34.0M | -$25.3M | -$29.2M | -$56.4M |
| Depreciation and amortization | $23,000 | $4,000 | $0 | $72,000 | $109,000 |
| Stock-based compensation | $2.3M | $3.3M | $3.3M | $4.3M | $8.1M |
| Capital expenditure | $0 | $117,000 | $0 | — | $0 |
| Free cash flow | -$33.1M | -$34.1M | -$25.3M | — | -$56.4M |
| Impairments | — | — | — | — | $0 |
Shares outstanding 33.4M · Free float 78.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.